The Midas List of the 2022 Forbes World's Best Venture Capitalists was officially announced on April 12, local time. Liang Zhenyu, managing partner of Qiming Venture Capital, and Kwong Ziping, founding managing partner, made the list.
Founded in 2001, the Forbes List of the World's Best Venture Capitalists is named after King Midas in Greek mythology, hence the "Goldfinger List". The release of this list is regarded as the "Oscar of the investment world".
Liang Yuyu made the list for the fourth consecutive time, ranking 61st this time, up 12 places from last year. In the previous three years, Liang Was ranked first in the field of healthcare in China, and has been consistently named the Best Female Venture Capitalist of Forbes China, and ranked first for the first time in 2022.
Liang and his team are always looking for projects that can truly promote the progress of China's healthcare system and meet the medical needs of patients around the world. As the first team in China to fully enter the medical and health field for venture capital, in the past ten years, Liang Zhenyu and his team have invested in Zaiding Pharmaceutical (NASDAQ:ZLAB, 09688.HK), CanSino Bio (688185.SH, 06185.HK), Gan & Lee Pharmaceutical (603087.SH), Nuohui Health (06606.HK), Qiming Medical (02500.HK), Schr dinger (NASDAQ: SDGR). ) and more than 170 companies in the field of medical and health care.
In the past 15 months, Qiming Venture Capital has received a total of 13 IPOs in the medical and health field, including "the first share of cancer early screening" Nuohui Health, China's recombinant protein leader Yiqiao Shenzhou, etc.
Liang Yuyu firmly believes that in the future, China will have a large number of global leaders in medical and health care, as a pathfinder and leader in investment in the field of medical and health, Qiming Venture Capital will work closely with entrepreneurs to find outstanding enterprises in the fields of new drug research and development, equipment, diagnosis, services and digital health, and jointly contribute to the high-quality development of China's medical and health industry.
Kwong was on the Forbes List of the World's Best Venture Capitalists for the third time, ranking 74th. Kwong co-founded Qiming Ventures in 2006 and led the investment of the TMT team.
As the founding managing partner of Qiming Venture Capital, Kwong Ziping has more than 30 years of corporate management and investment experience, and has been active in the front line of venture capital, leading the investment in a number of star companies such as Xiaomi Group, Stone Technology, Yunzhisheng, Qiniuyun, UBTECH, Hesai Technology, Wenyuan Zhixing and so on. Qiming Venture Capital has focused on the technology field for 15 years, covering artificial intelligence, enterprise services, semiconductors, blockchain and other fields.
Today, Qiming Ventures has been recognized as one of the most professional investment institutions in the field of AI, semiconductors and SaaS. In 2021, Kwong And his team laid out a multi-point layout in the field of "hard technology" and invested in many high-growth enterprises based on cutting-edge technology.
At present, China's investment and innovation environment is undergoing tremendous changes. Kwong Ziping believes that the key factor of innovation is the development of science and technology, China's new economy is out of a different path of innovation from the past, the new generation of entrepreneurs has a stronger ability to innovate in technology, and the products are becoming more and more internationally competitive. Qiming Venture Capital will always uphold the belief of being friends with entrepreneurs and provide more systematic services for investment enterprises.
At present, Qiming Venture Capital manages ten US dollar funds and six RMB funds, with a total asset under management of US$6.2 billion. Since its inception, it has focused on investing in outstanding enterprises in the early and growth stages of TMT, Healthcare and other industries. In 2021, Qiming Venture Capital completed more than 70 investments in the two major sectors of TMT and healthcare, with a total of 13 invested companies going public throughout the year, and more than 100 companies completing a new round of financing in 2021.
While achieving outstanding investment performance and being widely recognized by investors around the world, Qiming Ventures is also proactive in practicing social responsibility. In 2021, Qiming Venture Capital donated 100 million yuan to jointly launch the China Rural Revitalization Entrepreneurs Support Program with the China Foundation for Poverty Alleviation to contribute wisdom to China's rural revitalization and development, help rural revitalization, and promote common prosperity.
In the future, Qiming Venture Capital will continue to practice the ESG concept, find those outstanding enterprises that can play an important supporting role in economic and social development, and promote the landing of cutting-edge technologies and the transformation of scientific research achievements through ecosystem construction and resource integration, improve efficiency and enhance human well-being.